EA202192421A1 - Соединения и композиции, содержащие их для лечения гипертензии или сердечной недостаточности - Google Patents

Соединения и композиции, содержащие их для лечения гипертензии или сердечной недостаточности

Info

Publication number
EA202192421A1
EA202192421A1 EA202192421A EA202192421A EA202192421A1 EA 202192421 A1 EA202192421 A1 EA 202192421A1 EA 202192421 A EA202192421 A EA 202192421A EA 202192421 A EA202192421 A EA 202192421A EA 202192421 A1 EA202192421 A1 EA 202192421A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
treatment
compositions containing
hypertension
heart failure
Prior art date
Application number
EA202192421A
Other languages
English (en)
Inventor
Фабрис Балавуан
Дельфин Компер
Матильд Кек
Янник Марк
Катрин Ллорен-Кортес
Солен Э. Буатар
Original Assignee
Квантум Дженомикс
Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль
Сантр Насьональ Де Ля Решерш Сьянтифик
Коллеж Де Франс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Квантум Дженомикс, Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль, Сантр Насьональ Де Ля Решерш Сьянтифик, Коллеж Де Франс filed Critical Квантум Дженомикс
Publication of EA202192421A1 publication Critical patent/EA202192421A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к соединениям, к композициям, содержащим их, к способам получения соединений и к применению этих соединений в терапии. В частности, настоящее изобретение относится к соединению, которое является пригодным для лечения и предотвращения первичной и вторичной артериальной гипертензии, внезапного приступа, ишемии миокарда, сердечной и почечной недостаточности, инфаркта миокарда, заболевания периферических сосудов, диабетической протеинурии, синдрома X и глаукомы.
EA202192421A 2019-03-11 2020-03-11 Соединения и композиции, содержащие их для лечения гипертензии или сердечной недостаточности EA202192421A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305286 2019-03-11
PCT/EP2020/056483 WO2020182870A1 (en) 2019-03-11 2020-03-11 Compounds and compositions comprising the same for treating hypertension or heart failure

Publications (1)

Publication Number Publication Date
EA202192421A1 true EA202192421A1 (ru) 2021-12-22

Family

ID=65818483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192421A EA202192421A1 (ru) 2019-03-11 2020-03-11 Соединения и композиции, содержащие их для лечения гипертензии или сердечной недостаточности

Country Status (17)

Country Link
US (1) US11345658B2 (ru)
EP (1) EP3937924B1 (ru)
JP (1) JP2022520494A (ru)
KR (1) KR102401407B1 (ru)
CN (1) CN113784710A (ru)
AR (1) AR118302A1 (ru)
AU (1) AU2020235216B2 (ru)
BR (1) BR112021017158A2 (ru)
CA (1) CA3129677C (ru)
EA (1) EA202192421A1 (ru)
ES (1) ES2965293T3 (ru)
IL (1) IL285593B (ru)
MA (1) MA55275A (ru)
MX (1) MX2021011041A (ru)
TW (1) TW202100146A (ru)
WO (1) WO2020182870A1 (ru)
ZA (1) ZA202107513B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142629B (zh) * 2020-10-10 2021-09-14 西北工业大学 3-氨基磺酰基丙氨酸的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773712B1 (fr) 1998-01-16 2000-06-02 Inst Nat Sante Rech Med Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
EP2439192A1 (en) 2010-10-07 2012-04-11 Quantum Genomics Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid)

Also Published As

Publication number Publication date
US11345658B2 (en) 2022-05-31
JP2022520494A (ja) 2022-03-30
KR20210134037A (ko) 2021-11-08
ZA202107513B (en) 2023-01-25
WO2020182870A1 (en) 2020-09-17
AU2020235216A1 (en) 2021-09-09
CN113784710A (zh) 2021-12-10
US20220041548A1 (en) 2022-02-10
AU2020235216B2 (en) 2021-12-16
EP3937924A1 (en) 2022-01-19
BR112021017158A2 (pt) 2021-11-09
CA3129677C (en) 2023-01-03
TW202100146A (zh) 2021-01-01
IL285593A (en) 2021-09-30
IL285593B (en) 2022-07-01
ES2965293T3 (es) 2024-04-12
CA3129677A1 (en) 2020-09-17
MX2021011041A (es) 2021-10-13
EP3937924B1 (en) 2023-09-06
MA55275A (fr) 2022-01-19
KR102401407B1 (ko) 2022-05-23
AR118302A1 (es) 2021-09-29

Similar Documents

Publication Publication Date Title
EA202191150A1 (ru) Ингибиторы аминопептидазы а и содержащие их фармацевтические композиции
RU2008120295A (ru) Средства и способы для лечения нарушений свертываемости
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
EA202091267A1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA34397B1 (fr) Dérivés d'acide napht-2-ylacétique dans le traitement du sida
EA201491283A1 (ru) Ингибитор регулирующей апоптотические сигналы киназы
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA202191991A1 (ru) Новые производные гетеротрициклического соединения и их применение
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
EA202191151A1 (ru) Новые аминофосфиновые производные в качестве ингибиторов аминопептидазы а
PH12020550452A1 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201592287A1 (ru) Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения
MA38556A1 (fr) Inhibiteurs de bace1
EA202192421A1 (ru) Соединения и композиции, содержащие их для лечения гипертензии или сердечной недостаточности
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
EA202190841A1 (ru) Композиции для снижения уровней мочевой кислоты в сыворотке крови
EA201992152A1 (ru) Химические соединения
EA202192320A1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-[2-(трифторметил)пиридин-4-ил]-1h-пиразол-4-карбоксамида
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
EA202092326A1 (ru) Производные буметанида для лечения гипергидроза
EA200900862A1 (ru) Производные простациклина
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors